CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 49 enrolled
Drug / intervention
LY900014 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03433677
NCT03433677Phase 3Completed

A Prospective, Randomized, Double-Blind, Crossover Comparison Evaluating Compatibility and Safety of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Patients With Type 1 Diabetes (PRONTO-Pump)

Eli Lilly and Company·interventional·Posted Feb 14, 2018·Updated Oct 8, 2019

In Brief

A Phase 3 clinical trial evaluating LY900014 and Insulin lispro for Diabetes Type 1. Completed, enrolled 49 participants across 5 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an external continuous subcutaneous insulin infusion system in adult participants with type 1 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Type 1
CountriesSpain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedFeb 14, 2018
Enrollment StartFeb 21, 2018
Primary CompletionSep 4, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.4 years ago

Interventions

LY900014drug

Administered by CSII

Insulin lisprodrug

Administered by CSII